Related Experiment Video
Updated: Jun 6, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis
Junichi Kikuta1, Kaori Iwai, Yukihiko Saeki
1Department of Rheumatology and Clinical Research, National Osaka-Minami Medical Center, Osaka, Japan.
Abstract:
Therapeutics targeting sphingosine-1-phosphate (S1P), a kind of lipid mediator regulating immune cell trafficking, has been emerging rapidly as a novel line of regimen for autoimmune diseases, including rheumatoid arthritis (RA). Here, we propose that S1P-targeted therapy is beneficial not only for limiting inflammation but for preventing bone-resorptive disorders, such as osteoporosis, by controlling the migratory behavior of osteoclast precursors and therefore would be good for treating elderly female RA patients who suffer from postmenopausal osteoporosis and arthritis simultaneously.
Related Concept Videos
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Rheumatic Heart Disease III: Medical Management